Agilent Technologies (NYSE:A) Price Target Cut to $141.00

Agilent Technologies (NYSE:AGet Free Report) had its target price dropped by analysts at UBS Group from $155.00 to $141.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. UBS Group’s price target indicates a potential upside of 5.04% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Barclays upped their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Stifel Nicolaus reduced their target price on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating for the company in a research note on Thursday. Robert W. Baird reduced their target price on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research note on Thursday. Evercore ISI reduced their target price on shares of Agilent Technologies from $145.00 to $126.00 and set an “in-line” rating for the company in a research note on Thursday. Finally, Citigroup upped their target price on shares of Agilent Technologies from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $138.69.

View Our Latest Report on A

Agilent Technologies Trading Down 7.7 %

Shares of A stock traded down $11.24 on Thursday, hitting $134.24. The stock had a trading volume of 2,110,016 shares, compared to its average volume of 1,511,556. Agilent Technologies has a twelve month low of $96.80 and a twelve month high of $155.35. The firm has a market cap of $39.34 billion, a P/E ratio of 31.92, a PEG ratio of 3.98 and a beta of 1.13. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. The company has a fifty day moving average price of $144.13 and a two-hundred day moving average price of $137.02.

Agilent Technologies (NYSE:AGet Free Report) last announced its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.03. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.58 billion. During the same quarter in the previous year, the business earned $1.27 EPS. The firm’s revenue was down 8.4% on a year-over-year basis. As a group, analysts forecast that Agilent Technologies will post 5.5 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Heidi Fields sold 1,658 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the transaction, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Rodney Gonsalves sold 4,828 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $149.00, for a total transaction of $719,372.00. Following the completion of the transaction, the vice president now directly owns 21,329 shares in the company, valued at $3,178,021. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,610 shares of company stock valued at $9,220,333. 0.33% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in A. Gotham Asset Management LLC boosted its position in shares of Agilent Technologies by 246.7% during the 3rd quarter. Gotham Asset Management LLC now owns 54,437 shares of the medical research company’s stock worth $6,087,000 after acquiring an additional 38,737 shares in the last quarter. UBS Group AG boosted its position in Agilent Technologies by 84.5% in the fourth quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock valued at $45,281,000 after buying an additional 149,159 shares in the last quarter. DAVENPORT & Co LLC boosted its position in Agilent Technologies by 77.7% in the fourth quarter. DAVENPORT & Co LLC now owns 4,882 shares of the medical research company’s stock valued at $679,000 after buying an additional 2,135 shares in the last quarter. Wells Fargo & Company MN boosted its position in Agilent Technologies by 18.2% in the fourth quarter. Wells Fargo & Company MN now owns 508,184 shares of the medical research company’s stock valued at $70,653,000 after buying an additional 78,225 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in Agilent Technologies by 259.9% in the third quarter. Stifel Financial Corp now owns 119,582 shares of the medical research company’s stock valued at $13,375,000 after buying an additional 86,355 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Company Profile

(Get Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Stories

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.